Name | 5-cyano-7-nitro-3-oxido-1,3-benzothiazol-3-ium-2-carboxamide |
---|---|
Synonyms |
BTO-1
5-cyano-7-nitro-3-oxy-benzothiazole-2-carboxylic acid amide HMS3260F21 HMS3229L17 5-Cyano-7-nitro-2-benzothiazolecarboxamide-3-oxide |
Description | BTO-1 is a Polo-like kinase (Plk) inhibitor. BTO-1 is primarily used for phosphorylation and dephosphorylation applications[1][2]. |
---|---|
Related Catalog | |
Target |
Plx1 |
In Vitro | BTO-1 (50 μM; 4 hours; U20S cells) results in monopolar spindles in a comparable fraction of mitotic cells. BTO-1(20 μM; 1 hour; PTK cells) shows a dose-dependent reduction in phospho-Cdc25C. BTO-1(25 μM; 1 hour; PTK cells) shows about 20 % reduction in H3 phosphorylation compared to control cells. BTO-1 in HeLa cells results in a blockage of Rho and Rho-GEF recruitment, which is essential for the assembly of a functional contractile ring[1][2]. |
References |
Molecular Formula | C9H4N4O4S |
---|---|
Molecular Weight | 264.21700 |
Exact Mass | 263.99500 |
PSA | 166.40000 |
LogP | 2.43208 |
Storage condition | 2-8°C |
Symbol |
![]() GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H302-H312-H315-H319-H332-H335 |
Precautionary Statements | P261-P280-P305 + P351 + P338 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
Hazard Codes | Xn |
Risk Phrases | 20/21/22-36/37/38 |
Safety Phrases | 26-36/37 |
RIDADR | NONH for all modes of transport |
~% 40647-02-7 |
Literature: Wagner,K. et al. Chemische Berichte, 1973 , vol. 106, p. 640 - 654 |
Precursor 1 | |
---|---|
DownStream 0 |